Clinical Trials Logo

Immune Thrombocytopenia (ITP) clinical trials

View clinical trials related to Immune Thrombocytopenia (ITP).

Filter by:

NCT ID: NCT01054443 Terminated - Clinical trials for Immune Thrombocytopenia (ITP)

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Start date: March 18, 2010
Phase: Phase 2
Study type: Interventional

The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.

NCT ID: NCT00344149 Completed - Clinical trials for Immune Thrombocytopenia (ITP)

Rituximab as Second Line Treatment for ITP

Start date: June 2006
Phase: Phase 3
Study type: Interventional

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized thrombocytopenia. Splenectomy is the standard treatment for patients who fails the first-line treatment: corticosteroid. Rituximab, has recently emerged as a promising treatment for ITP. The aim of the study is to determine whether early treatment with Rituximab can result in durable remissions, and consequently, lead to the avoidance of splenectomy in a significant number of patients.